Universal Vaccine Against Influenza A Viruses

Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia State UniversityInfluenza, a contagious respiratory illness that infects the nose, throat and lungs, is among the leading causes of death in the United States, according to the Centers for Disease Control and Prevention (CDC). The CDC estimates influenza has resulted in between 12,000 and 56,000 deaths annually in the U.S. since 2010. Seasonal flu vaccines must be updated each year to match the influenza viruses that are predicted to be most common during the upcoming flu season, but protection doesn’t always meet expectations or new viruses emerge and manufacturers incorrectly guess which viruses will end up spreading. In 2009, the H1N1 pandemic caused 200,000 deaths during the first 12 months, and low vaccine effectiveness was also observed during the 2014-15 and 2016-17 flu seasons. A universal flu vaccine that offers broad protection against various viruses is urgently needed and would eliminate the limitations of seasonal flu vaccines.

Seasonal flu vaccines provide protective immunity against influenza viruses by targeting the exterior head of the virus’s surface protein, which is hem
(HA). The influenza virus trains the body to produce antibodies against inactivated virus particles containing the head of this protein, ideally preventing the head from attaching to receptors and stopping infection. However, the head is highly variable and is different for each virus, creating a need for better vaccines. This study uses a new approach and instead targets the inside portion of the HA protein known as the stalk, which is more conservative and offers the opportunity for universal protection.

In this study, the researchers found vaccinating mice with double-layered protein nanoparticles that target the stalk of this protein produces long-lasting immunity and fully protects them against various influenza A viruses. The findings are published in the journal Nature Communications.

Source: http://news.gsu.edu/

Vaccine That Is Programmable In One Week

MIT engineers have developed a new type of easily customizable vaccine that can be manufactured in one week, allowing it to be rapidly deployed in response to disease outbreaks. So far, they have designed vaccines against Ebola, H1N1 influenza, and Toxoplasma gondii (a relative of the parasite that causes malaria), which were 100 percent effective in tests in mice. The vaccine consists of strands of genetic material known as messenger RNA, which can be designed to code for any viral, bacterial, or parasitic protein. These molecules are then packaged into a molecule that delivers the RNA into cells, where it is translated into proteins that provoke an immune response from the host.

In addition to targeting infectious diseases, the researchers are using this approach to create cancer vaccines that would teach the immune system to recognize and destroy tumors.

MIT-Program-Vaccines_0 (1)

This nanoformulation approach allows us to make vaccines against new diseases in only seven days, allowing the potential to deal with sudden outbreaks or make rapid modifications and improvements,” says Daniel Anderson, an associate professor in MIT’s Department of Chemical Engineering and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).

Anderson is the senior author of a paper describing the new vaccines in the Proceedings of the National Academy of Sciences. The project was led by Jasdave Chahal, a postdoc at MIT’s Whitehead Institute for Biomedical Research, and Omar Khan, a postdoc at the Koch Institute; both are the first authors of the paper.

Source: http://news.mit.edu/

Vaccine Against Herpes, Potentially HIV

An effective vaccine against the virus that causes genital herpes has evaded researchers for decades. But now, researchers from the University of Illinois at Chicago (UIC) working with scientists from the Kiel University (Germany) have shown that zinc-oxide nanoparticles shaped like jacks can prevent the virus from entering cells, and help natural immunity to develop.

zinc oxyde tetrapod

We call the virus-trapping nanoparticle a microbivac, because it possesses both microbicidal and vaccine-like properties,” says corresponding author Deepak Shukla, professor of ophthalmology and microbiology & immunology in the UIC College of Medicine. “It is a totally novel approach to developing a vaccine against herpes, and it could potentially also work for HIV and other viruses,” he said. The particles could serve as a powerful active ingredient in a topically-applied vaginal cream that provides immediate protection against herpes virus infection while simultaneously helping stimulate immunity to the virus for long-term protection, explained Shukla. Herpes simplex virus-2, which causes serious eye infections in newborns and immunocompromised patients as well as genital herpes, is one of the most common human viruses.

According to the Centers for Disease Control and Prevention, about 15 percent of people from ages 14-49 carry HSV-2, which can hide out for long periods of time in the nervous system. The genital lesions caused by the virus increase the risk for acquiring human immunodeficiency virus, or HIV. “Your chances of getting HIV are three to four times higher if you already have genital herpes, which is a very strong motivation for developing new ways of preventing herpes infection,” Shukla said. Treatments for HSV-2 include daily topical medications to suppress the virus and shorten the duration of outbreaks, when the virus is active and genital lesions are present. However, drug resistance is common, and little protection is provided against further infections. Efforts to develop a vaccine have been unsuccessful because the virus does not spend much time in the bloodstream, where most traditional vaccines do their work.
The tetrapod-shaped zinc-oxide nanoparticles, called ZOTEN, have negatively charged surfaces that attract the HSV-2 virus, which has positively charged proteins on its outer envelope. ZOTEN nanoparticles were synthesized using technology developed by material scientists at Germany’s Kiel University and protected under a joint patent with UIC. When bound to the nanoparticles, HSV-2 cannot infect cells.

Results of the study are published in The Journal of Immunology.

Source: https://news.uic.edu/

Vaccine For Type 1 Diabetes?

New findings suggesting that children diagnosed with type 1 diabetes before the age of seven have a very different form of the disease could lead to new ways of treating it, potentially including a vaccine. Nine year old Bethan has Type 1 diabetes. She uses an omnipod pump to deliver insulin when required, while Mum Lizzie watches her diet. Before her diagnosis, life was tough.

type1 diabetes
I felt very weak and tired all the time“complains BethanWestcott-Storer, the nine-year old Diabetes type 1 patient.

Her mother comments: “We noticed that she’d become quite thin, she’d lost a lot of weight, but she didn’t have all of the signs that other children normally have with type 1 – she didn’t have the excess thirst and urinating. Just lost a lot of weight, so she’s been diagnosed for 15 months now.”
Now Bethan’s the picture of health…and the news could get better. The University of Exeter Medical School (UK)  has made a major discovery that could lead to better treatment and even prevention of the disease.

It’s always been thought that when people get type 1 diabetes they’ve lost as many as 90 percent of their insulin producing cells from their pancreas. What we’ve found is that while that might be the case for the younger children it certainly doesn’t appear to be true for those that are older. They have quite a considerable reserve of cells left. That’s a new insight and it might mean that if we could reactivate those cells we could help them to cope better with their illness.“, says Prof. Noel Morgan, of the University of Exeter Medical School.

Researchers examined around 100 pancreas samples in Exeter‘s biobank. They found that those diagnosed before the age of seven develop a more aggressive form of the disease than teenagers.

Those samples are extremely important because we do not understand the underlying disease process that goes on in these individuals and it’s that recent diagnosis that’s critical for us to actually look inside the pancreas and see what is going wrong, and the pancreas itself is an extremely inaccessible organ“, says Dr. Sarah Richardson, from the University of Exeter Medical School. “We’re trying to understand what the trigger is and it may be possible to use a vaccine to stop the triggering process, but it might also be able to use a different kind of vaccine to target the specific immune cells that are causing the illness, and that’s where the excitement lies“, adds Prof.  Morgan. Although well adjusted to her daily routine, Bethan also has high hopes for the ongoing research: “If one day in the future they find a cure or something lots and lots of people are going to be really happy“!

Source: http://www.reuters.com/

How To Prevent Babies Bronchiolitis

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.

Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a respiratory virus that infects the lungs and breathing passages. Healthy people usually experience mild, cold-like symptoms and recover in a week or two. But RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children younger than 1 year of age in the United States. In addition, RSV is being recognized more often as a significant cause of respiratory illness in older adults.


Recombinant engineered nanoparticle vaccines might be developed to prevent highly contagious respiratory pathogens such as RSV, as reported in this study,” said Dr. Sang-Moo Kang, a professor in the Institute for Biomedical Sciences at Georgia State.

In the study, mice were vaccinated with either 1) FG VLPs or virus-like nanoparticles expressing RSV fusion (F) and attachment glycoproteins (G) or 2) FI-RSV or formalin-inactivated RSV, which failed clinical vaccine trials in the 1960s because it caused severe vaccine-enhanced respiratory disease. The mice were infected with live RSV pathogen one year later after vaccination.

Mice vaccinated with FG VLPs showed no obvious sign of severe pulmonary disease in tissue examinations upon RSV infection and significantly lower levels of eosinophils, T-cell infiltration and inflammatory cytokines, but higher levels of antibodies and interferon-g antiviral cytokine, which are correlated with protection against RSV disease.

Their findings, have been published in the International Journal of Nanomedicine, and suggest this vaccine induces long-term protection against RSV. There is no licensed RSV vaccine.

Source; http://news.gsu.edu/

Could Nanotechnology Kill Ebola?

The Ebola virus out­break in West Africa has claimed more than 1200 lives since Feb­ruary and has infected thou­sands more. Coun­tries such as Nigeria and Liberia have declared health emer­gen­cies, while the World Health Orga­ni­za­tion dis­cuss ways to battle the outbreak. There is no known vac­cine, treat­ment, or cure for Ebola, which is con­tracted through the bodily fluids of an infected person or animal. But that doesn’t mean there’s not hope. In fact, Chem­ical Engi­neering Chair Thomas Webster’s lab (NorthEastern University) is cur­rently working on one pos­sible solu­tion for fighting Ebola and other deadly viruses: nanotechnology.
It has been very hard to develop a vac­cine or treat­ment for Ebola or sim­ilar viruses because they mutate so quickly,” explained Web­ster, the editor-​​in-​​chief of the Inter­na­tional Journal of Nanomed­i­cine. “In nan­otech­nology we turned our atten­tion to devel­oping nanopar­ti­cles that could be attached chem­i­cally to the viruses and stop them from spreading.
One par­ticle that is showing great promise is gold. According to Web­ster, gold nanopar­ti­cles are cur­rently being used to treat cancer. Infrared waves, he explained, heat up the gold nanopar­ti­cles, which, in turn, attack and destroy every­thing from viruses to cancer cells, but not healthy cells.

Rec­og­nizing that a larger sur­face area would lead to a quicker heat-​​up time, Webster’s team cre­ated gold nanos­tars. “The star has a lot more sur­face area, so it can heat up much faster than a sphere can,” Web­ster said. “And that greater sur­face area allows it to attack more viruses once they absorb to the par­ti­cles.” In addi­tion to the gold nanos­tars, Webster’s lab is also gen­er­ating a nanopar­ticle that would serve as a “virus decoy,” chem­i­cally attracting the virus to attack it rather than healthy cells.

Source: http://www.northeastern.edu/

Very Efficient Dust-Mite Allergy Vaccine

If you’re allergic to dust mites (and chances are you are), help may be on the way.
Researchers at the University of Iowa (UI) have developed a vaccine that can combat dust-mite allergies by naturally switching the body’s immune response. In animal tests, the nano-sized vaccine package lowered lung inflammation by 83 percent despite repeated exposure to the allergens, according to the paper, published in the AAPS (American Association of Pharmaceutical Scientists) Journal. One big reason why it works, the researchers contend, is because the vaccine package contains a booster that alters the body’s inflammatory response to dust-mite allergens.
What is new about this is we have developed a vaccine against dust-mite allergens that hasn’t been used before,” says Aliasger Salem, professor in pharmaceutical sciences at the UI and a corresponding author on the paper.
Dust mites are ubiquitous, microscopic buggers who burrow in mattresses, sofas, and other homey spots. They are found in 84 percent of households in the United States, according to a published, national survey. Preying on skin cells on the body, the mites trigger allergies and breathing difficulties among 45 percent of those who suffer from asthma, according to some studies. Prolonged exposure can cause lung damage.
Usual treatment is limited to getting temporary relief from inhalers or undergoing regular exposure to build up tolerance, which is long term and holds no guarantee of success.
Our research explores a novel approach to treating mite allergy in which specially-encapsulated miniscule particles are administered with sequences of bacterial DNA that direct the immune system to suppress allergic immune responses,” says Peter Thorne, public health professor at the UI and a contributing author on the paper. “This work suggests a way forward to alleviate mite-induced asthma in allergy sufferers.”

Source: http://now.uiowa.edu/

Nanosponge Vaccine Fights MRSA Toxins

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This “nanosponge vaccine” enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA—both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the journal Nature Nanotechnology.nanosponge-vaccine
The glowing yellow specks in the image show uptake of the nanosponge vaccine by a mouse dendritic cell, which is an immune-system cell. The nanovaccine’s detained alpha-haemolysin toxins were labeled with a dye which glows yellow and can be seen glowing after uptake by the dendritic cell. The cell membrane is stained red and the nucleus is stained blue
With our toxoid vaccine, we don’t have to worry about antibiotic resistance. We directly target the alpha-haemolysin toxin,” said Liangfang Zhang, a nanoengineering professor at UC San Diego Jacobs School of Engineering and the senior author on the paper published in Nature Technology. Targeting the alpha-haemolysin toxin directly has another perk. “These toxins create a toxic environment that serves as a defense mechanism which makes it harder for the immune system to fight Staph bacteria,” explained Zhang.

Source: http://ucsdnews.ucsd.edu/

How To Protect Vaccine And Provoke Immune Response

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces. Vaccines can be delivered to the lungs via an aerosol spray, but the lungs often clear away the vaccine before it can provoke an immune response. To overcome that, MIT engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response — not only in the lungs, but also in mucosal surfaces far from the vaccination site, such as the gastrointestinal and reproductive tracts.
Nanoparticle protects vaccine
This is a good example of a project where the same technology can be applied in cancer and in infectious disease. It’s a platform technology to deliver a vaccine of interest,” says Irvine, who is a member of MIT’s Koch Institute for Integrative Cancer Research and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard University.

Irvine and colleagues describe the nanoparticle vaccine in the journal Science Translational Medicine.
Source: http://web.mit.edu/

Nanoengineered Capsules To Fight Cancer

University of Melbourne researchers have developed an efficient system to coat tiny objects, such as bacterial cells, with thin films that assemble themselves which could have important implications for drug delivery as well as biomedical and environmental applications.

Professor Frank Caruso from the Department of Chemical and Biomolecular Engineering at the University of Melbourne and his team have developed a new strategy to coat microscopic materials, leading to a new-generation particle system with engineered properties. This is expected to underpin advances in the delivery of therapeutics in the areas of cancer, vaccines, cardiovascular disease and neural health. The capsules can be engineered to degrade under different conditions, providing opportunities for the timed release of substances contained inside the capsules.
molecular-Nanoengineered capsules are attracting much attention as drug carriers, as they have the potential to improve the delivery and effectiveness of drugs while reducing their side effects,” Professor Caruso said. “Our engineered particle system can be assembled rapidly from naturally occurring materials (minerals and nutrients) with specific physical and chemical properties, making it a versatile platform for various applications.

The result ss fo the research has been published in the journal Science.
Source: http://themelbourneengineer.eng.unimelb.edu.au/

Synthetic Nano-Engineered Vaccines

Scientists at the Biodesign Institute at Arizona State University have turned to a promising field called DNA nanotechnology to make an entirely new class of synthetic vaccines. In a study published in the journal Nano Letters, Biodesign immunologist Yung Chang joined forces with her colleagues, including DNA nanotechnology innovator Hao Yan, to develop the first vaccine complex that could be delivered safely and effectively by piggybacking onto self-assembled, three-dimensional DNA nanostructures.

When Hao treated DNA not as a genetic material, but as a scaffolding material, that made me think of possible applications in immunology,” said Chang, an associate professor in the School of Life Sciences and a researcher in they Biodesign Institute’s Center for Infectious Diseases and Vaccinology. “

Source: https://asunews.asu.edu/20120725_syntheticvaccines